(Q48463573)

11 February 2018

title

A phase II trial of temsirolimus in second-line metastatic urothelial cancer. (English)

1 reference

11 February 2018

main subject

phase II clinical trial

0 references

author name string

H Gerullis

1

1 reference

11 February 2018

C Eimer

2

1 reference

11 February 2018

T H Ecke

3

1 reference

11 February 2018

E Georgas

4

1 reference

11 February 2018

C Freitas

5

1 reference

11 February 2018

S Kastenholz

6

1 reference

11 February 2018

C Arndt

7

1 reference

11 February 2018

C Heusch

8

1 reference

11 February 2018

T Otto

9

1 reference

11 February 2018

publication date

25 March 2012

1 reference

11 February 2018

published in

Medical Oncology

1 reference

11 February 2018

volume

29

1 reference

11 February 2018

page(s)

2870-2876

1 reference

11 February 2018

issue

4

1 reference

11 February 2018

https://scigraph.springernature.com/pub.10.1007/s12032-012-0216-x

exact match

0 references

cites work

Chemotherapy for metastatic or unresectable bladder cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0216-X

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0216-X

Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0216-X

The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0216-X

Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0216-X

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0216-X

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0216-X

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0216-X

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0216-X

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0216-X

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0216-X

A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0216-X

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0216-X

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0216-X

Second-line therapy in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0216-X

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0216-X

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0216-X

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

21 January 2018

1 reference

12 December 2020

mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma

1 reference

12 December 2020

Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance

1 reference

12 December 2020

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

12 December 2020

Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer

1 reference

12 December 2020

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

12 December 2020

10.1007/S12032-012-0216-X

Identifiers

DOI

1 reference

11 February 2018

PubMed ID

22447503

1 reference

11 February 2018